Raymond James Financial, Inc. Reaffirms “Strong-Buy” Rating for Paratek Pharmaceuticals, Inc. (PRTK)
Raymond James Financial, Inc. reiterated their strong-buy rating on shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) in a research report report published on Thursday. Raymond James Financial, Inc. currently has a $36.00 price objective on the specialty pharmaceutical company’s stock.
A number of other analysts have also issued reports on the company. Cantor Fitzgerald reaffirmed an overweight rating and issued a $50.00 price target on shares of Paratek Pharmaceuticals in a research note on Thursday, June 22nd. HC Wainwright lifted their price target on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a buy rating in a research note on Tuesday, July 18th. BidaskClub lowered Paratek Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Monday, July 24th. Finally, Zacks Investment Research raised Paratek Pharmaceuticals from a hold rating to a buy rating and set a $21.00 price target on the stock in a research note on Saturday, August 5th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Paratek Pharmaceuticals presently has an average rating of Buy and a consensus price target of $37.44.
Shares of Paratek Pharmaceuticals (PRTK) opened at 24.55 on Thursday. Paratek Pharmaceuticals has a 52 week low of $9.80 and a 52 week high of $26.10. The company has a 50-day moving average of $21.57 and a 200-day moving average of $20.40. The stock’s market capitalization is $681.53 million.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.25. The firm had revenue of $7.51 million during the quarter, compared to analyst estimates of $7.50 million.
TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/27/raymond-james-financial-inc-reaffirms-strong-buy-rating-for-paratek-pharmaceuticals-inc-prtk.html.
In other Paratek Pharmaceuticals news, VP Adam Woodrow sold 3,800 shares of the business’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total transaction of $89,604.00. Following the transaction, the vice president now owns 69,500 shares of the company’s stock, valued at $1,638,810. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Evan Loh sold 4,351 shares of the business’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total value of $102,596.58. Following the transaction, the chief operating officer now directly owns 112,783 shares in the company, valued at approximately $2,659,423.14. The disclosure for this sale can be found here. Insiders have sold 21,960 shares of company stock worth $524,342 in the last three months. 4.90% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in PRTK. Vanguard Group Inc. raised its position in Paratek Pharmaceuticals by 19.8% in the second quarter. Vanguard Group Inc. now owns 867,616 shares of the specialty pharmaceutical company’s stock worth $20,909,000 after buying an additional 143,316 shares during the period. State Street Corp raised its position in Paratek Pharmaceuticals by 112.3% in the second quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock worth $14,850,000 after buying an additional 325,856 shares during the period. Renaissance Technologies LLC raised its position in Paratek Pharmaceuticals by 44.0% in the second quarter. Renaissance Technologies LLC now owns 596,749 shares of the specialty pharmaceutical company’s stock worth $14,382,000 after buying an additional 182,236 shares during the period. Franklin Resources Inc. raised its position in Paratek Pharmaceuticals by 106.8% in the second quarter. Franklin Resources Inc. now owns 508,066 shares of the specialty pharmaceutical company’s stock worth $12,244,000 after buying an additional 262,374 shares during the period. Finally, C WorldWide Group Holding A S raised its position in Paratek Pharmaceuticals by 449.3% in the second quarter. C WorldWide Group Holding A S now owns 439,400 shares of the specialty pharmaceutical company’s stock worth $10,590,000 after buying an additional 359,400 shares during the period. 77.96% of the stock is currently owned by institutional investors.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Stock Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.